Follicle-Stimulating Hormone (FSH) Testing: Technical Principles, Methods, and Clinical Applications

Follicle-Stimulating Hormone (FSH) testing is a cornerstone laboratory assay for evaluating the hypothalamic-pituitary-gonadal axis and reproductive endocrine function in both men and women. This comprehensive technical guide covers FSH sample requirements, analytical methods, reference intervals, clinical applications, and quality assurance standards for laboratory professionals, clinicians, and researchers.

Technical Overview

Follicle-Stimulating Hormone (FSH) is a gonadotropic glycoprotein hormone synthesized and secreted by the gonadotroph cells of the anterior pituitary gland. With a molecular weight of approximately 35 kDa, FSH is a heterodimer composed of two non-covalently linked subunits: a common alpha subunit shared with luteinizing hormone (LH), thyroid-stimulating hormone (TSH), and human chorionic gonadotropin (hCG), and a hormone-specific beta subunit that confers receptor binding specificity and biological activity. Carbohydrate side chains account for roughly 30% of its molecular mass and significantly influence its circulatory half-life of approximately 3 to 4 hours.

FSH secretion is regulated by pulsatile gonadotropin-releasing hormone (GnRH) from the hypothalamus and modulated by negative feedback from sex steroids (estradiol and progesterone in females, testosterone in males) and inhibin B produced by the gonads. Activin stimulates FSH production, while follistatin antagonizes this effect.

• In females, FSH promotes follicular recruitment and growth, granulosa cell proliferation, aromatase activity, and estradiol synthesis during the follicular phase of the menstrual cycle.
• In males, FSH acts on Sertoli cells to support spermatogenesis and the secretion of androgen-binding protein within the seminiferous tubules.
• Circulating FSH concentrations serve as a sensitive biochemical indicator of gonadal function, ovarian reserve, pubertal development, and pituitary disorders.

Testing Samples

Serum

Serum is the most widely used matrix for FSH measurement. Venous blood is collected into a plain tube or serum separator tube, allowed to clot for 30 minutes at room temperature, and then centrifuged to separate the serum. Serum FSH is stable under standard laboratory transport conditions and is compatible with all major automated immunoassay platforms.

Plasma

Plasma collected in EDTA or lithium heparin anticoagulant tubes is acceptable for many assay systems, provided the analytical method has been validated for this matrix by the reagent manufacturer. Gel barriers and anticoagulant types should always be confirmed against assay specifications to avoid matrix-related bias.

Urine

Spot or timed urine collections may be used in specialized settings, such as pediatric endocrinology evaluations, where urinary gonadotropin measurement with creatinine normalization provides supplementary information about pulsatile pituitary secretion.

Sample Handling and Stability

• Centrifuge whole blood samples within 2 hours of collection to minimize glycolytic and cellular interference.
• Store samples at 2–8°C for up to 48–72 hours if testing is delayed, in accordance with the assay manufacturer's stability claims.
• For long-term storage, freeze samples at -20°C or below -70°C and avoid repeated freeze-thaw cycles.
• Reject or flag grossly hemolyzed, lipemic, or icteric specimens, as these may interfere with optical detection systems.
• Patients taking high-dose biotin supplements should discontinue use for at least 72 hours before sampling, since biotin can interfere with streptavidin-biotin-based immunoassays.

Testing Items

The core analytical output of FSH testing is the quantitative concentration of the hormone in biological fluid, reported in mIU/mL or IU/L. Testing is frequently performed as part of a broader reproductive endocrine panel to strengthen clinical interpretation.

• Basal FSH: measured on menstrual cycle day 2 to 4 to assess ovarian reserve and baseline pituitary-gonadal status.
• FSH/LH ratio: useful in the evaluation of polycystic ovary syndrome (PCOS) and hypothalamic amenorrhea, with an elevated ratio suggesting diminished ovarian reserve.
• Combined endocrine panels: LH, estradiol (E2), anti-Müllerian hormone (AMH), inhibin B, prolactin, total testosterone, and sex hormone-binding globulin (SHBG).
• Dynamic function tests: GnRH stimulation testing to differentiate pituitary from hypothalamic causes of hypogonadism, and the clomiphene citrate challenge test for ovarian reserve screening.

Typical adult reference intervals are assay-dependent, but commonly cited ranges include approximately 3.5–12.5 mIU/mL in the follicular phase, 4.7–21.5 mIU/mL at mid-cycle, 1.7–7.7 mIU/mL in the luteal phase, 25.8–134.8 mIU/mL after menopause for females, and 1.5–12.4 mIU/mL for adult males. Laboratories must establish or verify their own intervals for the specific population served.

Testing Methods

Chemiluminescent Immunoassay (CLIA)

CLIA is the predominant methodology on modern automated immunoanalyzers. A two-site sandwich format is employed, typically using a capture antibody directed against the beta subunit and an acridinium- or alkaline phosphatase-labeled detection antibody, with signal generation proportional to FSH concentration. CLIA offers wide dynamic range, excellent precision, and rapid turnaround.

Electrochemiluminescence Immunoassay (ECLIA)

ECLIA uses ruthenium-labeled antibodies and tripropylamine-based signal generation on streptavidin-coated solid phases. It provides high analytical sensitivity, low background signal, and robust automation, making it a mainstay in high-volume clinical laboratories.

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA remains a cost-effective option for research laboratories, smaller facilities, and batch testing. Microwell plate formats with HRP/TMB colorimetric detection deliver acceptable performance when operated with disciplined quality control and standardized incubation conditions.

Legacy and Alternative Methods

Radioimmunoassay (RIA) and immunoradiometric assay (IRMA) were historically important but have largely been replaced by non-isotopic techniques. Fluoroimmunoassay (FIA) and time-resolved fluoroimmunoassay continue to be used on certain platforms. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) for intact gonadotropins remains an area of research, with immunoassays retaining clinical dominance.

Analytical Performance and Quality Assurance

• Assay calibration should be traceable to the current WHO International Standard for FSH, consistent with the metrological traceability principles of ISO 17511.
• Precision, detection capability, and linearity should be verified following CLSI evaluation protocols (for example, EP05 for precision, EP17 for limits of detection, EP06 for linearity, and EP07 for interference).
• Laboratories should participate in external quality assessment or proficiency testing programs and maintain accreditation in accordance with ISO 15189 for medical laboratories.
• Known analytical interferences include heterophilic antibodies, human anti-mouse antibodies (HAMA), high-dose biotin, and the high-dose hook effect at extreme concentrations.
• Result interpretation must account for sex, age, menstrual cycle phase, menopausal status, and concurrent hormone therapy.

Applications

FSH testing supports a broad spectrum of clinical decision-making across reproductive medicine, endocrinology, pediatrics, and oncology follow-up care.

• Infertility evaluation in both female and male partners, as a first-line endocrine assessment.
• Ovarian reserve estimation in women planning pregnancy or undergoing assisted reproductive technology (ART) procedures such as IVF.
• Confirmation of perimenopause and menopause, where persistently elevated FSH with low estradiol indicates ovarian failure.
• Classification of amenorrhea and menstrual disorders into hypergonadotropic (primary gonadal) versus hypogonadotropic (central) etiologies.
• Supportive evaluation of polycystic ovary syndrome and hypothalamic dysfunction.
• Diagnosis and monitoring of hypopituitarism, pituitary adenomas, and other hypothalamic-pituitary disorders.
• Investigation of precocious or delayed puberty in children and adolescents.
• Assessment of male hypogonadism, oligospermia, and azoospermia, including differentiation of primary from secondary testicular failure.
• Adjunctive endocrine characterization of genetic syndromes such as Turner syndrome and Klinefelter syndrome.
• Monitoring of gonadotropin therapy during ovulation induction and controlled ovarian stimulation cycles.

FAQ

When should FSH testing be performed during the menstrual cycle?

For basal ovarian reserve assessment, FSH should be measured on cycle day 2, 3, or 4, when estradiol feedback is at its lowest and FSH reflects true follicular recruitment status. Timing is less critical for men, postmenopausal women, and prepubertal children, although morning collection is generally preferred.

Is fasting required before FSH testing?

Fasting is not strictly required because FSH is not acutely affected by food intake. However, patients should avoid strenuous exercise and acute stress before sampling, and collection timing should be consistent for serial monitoring.

What does an elevated FSH level indicate?

In women, elevated FSH commonly indicates diminished ovarian reserve, primary ovarian insufficiency, or menopause, reflecting reduced estradiol and inhibin B negative feedback. In men, high FSH suggests primary testicular failure or impaired spermatogenesis, as seen in Klinefelter syndrome or after gonadal damage.

What does a low FSH level indicate?

Low FSH suggests hypogonadotropic hypogonadism arising from hypothalamic or pituitary dysfunction, and may also be observed in PCOS, severe stress, significant weight loss, or during use of exogenous hormones including combined oral contraceptives.

Can medications affect FSH results?

Yes. Estrogen-containing contraceptives, hormone replacement therapy, GnRH agonists or antagonists, and glucocorticoids suppress gonadotropin secretion, while high-dose biotin can cause spurious results on certain immunoassay platforms. Clinicians should document all relevant medications and supplements when ordering testing.

How should FSH results be interpreted clinically?

FSH should never be interpreted in isolation. Conclusions require integration with LH, estradiol, AMH, patient age, menstrual history, and imaging findings. Laboratories should provide assay-specific reference intervals stratified by sex, age group, and physiological status to support accurate interpretation.